Nifty
Sensex
:
:
23587.50
78041.59
-364.20 (-1.52%)
-1176.46 (-1.49%)

Pharmaceuticals & Drugs

Rating :
N/A

BSE: 543904 | NSE: MANKIND

2805.20
20-Dec-2024
  • Open
  • High
  • Low
  • Previous Close
  •  2907.80
  •  2908.00
  •  2755.00
  •  2891.05
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  671820
  •  19044.33
  •  2922.90
  •  1901.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,15,661.07
  • 54.69
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,14,940.42
  • N/A
  • 10.63

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.87%
  • 1.17%
  • 1.55%
  • FII
  • DII
  • Others
  • 12.37%
  • 9.33%
  • 0.71%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 9.92

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 4.97

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 10.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
47.75
53.63
61.48
76.71
P/E Ratio
53.55
47.68
41.59
33.33
Revenue
10335
12165
14519
16614
EBITDA
2816
3158
3932
4655
Net Income
1913
2145
2463
3091
ROA
17.7
13.6
12.2
13.7
P/Bk Ratio
10.94
8.71
7.31
6.07
ROE
22.77
20.41
19
19.62
FCFF
1851.78
-5249.96
2393.43
2997.95
FCFF Yield
1.85
-5.23
2.38
2.99

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
3,076.51
2,708.10
13.60%
2,893.42
2,578.62
12.21%
2,441.10
2,052.67
18.92%
2,606.96
2,090.93
24.68%
Expenses
2,226.47
2,025.45
9.92%
2,211.66
1,923.81
14.96%
1,850.00
1,635.99
13.08%
2,000.45
1,653.89
20.95%
EBITDA
850.04
682.65
24.52%
681.76
654.81
4.12%
591.10
416.68
41.86%
606.50
437.04
38.77%
EBIDTM
27.63%
25.21%
23.56%
25.39%
24.21%
20.30%
23.26%
20.90%
Other Income
109.43
59.98
82.44%
100.60
58.62
71.61%
92.13
47.51
93.92%
70.13
37.14
88.83%
Interest
7.10
8.62
-17.63%
10.91
6.34
72.08%
9.38
5.15
82.14%
9.18
12.77
-28.11%
Depreciation
105.62
96.49
9.46%
107.74
87.35
23.34%
104.69
84.52
23.86%
109.73
84.79
29.41%
PBT
846.75
637.52
32.82%
663.71
619.74
7.09%
569.16
374.51
51.97%
557.73
376.63
48.08%
Tax
190.44
129.81
46.71%
124.55
130.28
-4.40%
94.98
83.59
13.63%
102.52
83.27
23.12%
PAT
656.31
507.71
29.27%
539.16
489.46
10.15%
474.18
290.93
62.99%
455.21
293.36
55.17%
PATM
21.33%
18.75%
18.63%
18.98%
19.42%
14.17%
17.46%
14.03%
EPS
16.31
12.51
30.38%
13.39
12.15
10.21%
11.76
7.13
64.94%
11.33
7.09
59.80%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Net Sales
11,017.99
10,334.77
8,749.43
7,781.56
6,214.43
Net Sales Growth
16.84%
18.12%
12.44%
25.22%
 
Cost Of Goods Sold
3,252.30
3,209.70
2,913.64
2,421.73
1,780.60
Gross Profit
7,765.69
7,125.08
5,835.79
5,359.83
4,433.82
GP Margin
70.48%
68.94%
66.70%
68.88%
71.35%
Total Expenditure
8,288.58
7,798.19
6,847.50
5,791.01
4,565.32
Power & Fuel Cost
-
129.30
108.96
103.13
82.53
% Of Sales
-
1.25%
1.25%
1.33%
1.33%
Employee Cost
-
2,274.73
1,918.47
1,620.59
1,415.78
% Of Sales
-
22.01%
21.93%
20.83%
22.78%
Manufacturing Exp.
-
174.04
150.57
189.81
140.14
% Of Sales
-
1.68%
1.72%
2.44%
2.26%
General & Admin Exp.
-
982.88
1,000.80
626.47
451.75
% Of Sales
-
9.51%
11.44%
8.05%
7.27%
Selling & Distn. Exp.
-
928.75
638.11
708.17
587.73
% Of Sales
-
8.99%
7.29%
9.10%
9.46%
Miscellaneous Exp.
-
98.80
116.96
121.10
106.78
% Of Sales
-
0.96%
1.34%
1.56%
1.72%
EBITDA
2,729.40
2,536.58
1,901.93
1,990.55
1,649.11
EBITDA Margin
24.77%
24.54%
21.74%
25.58%
26.54%
Other Income
372.29
280.86
128.57
196.03
170.95
Interest
36.57
35.05
45.76
59.80
21.16
Depreciation
427.78
398.25
325.92
166.62
118.97
PBT
2,637.35
2,384.14
1,658.81
1,960.15
1,679.93
Tax
512.49
457.59
361.56
521.64
398.58
Tax Rate
19.43%
19.19%
21.80%
26.61%
23.73%
PAT
2,124.86
1,912.89
1,281.86
1,433.48
1,265.42
PAT before Minority Interest
2,101.47
1,941.77
1,309.68
1,452.96
1,293.03
Minority Interest
-23.39
-28.88
-27.82
-19.48
-27.61
PAT Margin
19.29%
18.51%
14.65%
18.42%
20.36%
PAT Growth
34.36%
49.23%
-10.58%
13.28%
 
EPS
53.04
47.75
32.00
35.78
31.59

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Shareholder's Funds
9,363.09
7,435.22
6,155.23
4,722.00
Share Capital
40.06
40.06
40.06
40.06
Total Reserves
9,299.78
7,395.10
6,115.17
4,681.94
Non-Current Liabilities
187.34
199.24
168.68
107.33
Secured Loans
24.87
23.15
48.94
57.42
Unsecured Loans
0.00
0.00
0.25
0.25
Long Term Provisions
123.12
97.89
80.00
72.24
Current Liabilities
2,119.73
1,863.14
2,623.46
1,353.40
Trade Payables
1,102.99
1,008.18
1,076.40
666.97
Other Current Liabilities
429.58
386.05
472.89
282.77
Short Term Borrowings
151.47
115.02
794.59
158.35
Short Term Provisions
435.69
353.89
279.59
245.30
Total Liabilities
11,882.86
9,685.67
9,108.45
6,323.62
Net Block
4,539.96
4,245.28
3,582.77
1,658.94
Gross Block
5,909.75
5,233.03
4,246.54
2,160.04
Accumulated Depreciation
1,369.79
987.75
663.78
501.10
Non Current Assets
5,314.63
5,357.80
4,701.63
2,416.98
Capital Work in Progress
281.79
550.15
701.47
371.95
Non Current Investment
309.81
270.95
235.01
205.80
Long Term Loans & Adv.
163.97
187.54
163.88
158.07
Other Non Current Assets
13.79
98.51
13.09
16.72
Current Assets
6,565.52
4,324.56
4,403.84
3,906.64
Current Investments
2,258.11
1,075.47
874.46
1,306.17
Inventories
1,553.46
1,498.46
1,760.24
1,183.54
Sundry Debtors
848.28
576.42
388.17
330.61
Cash & Bank
1,197.97
453.20
405.94
700.74
Other Current Assets
707.70
64.29
170.74
109.78
Short Term Loans & Adv.
603.60
656.71
804.29
275.79
Net Current Assets
4,445.79
2,461.42
1,780.37
2,553.24
Total Assets
11,880.15
9,682.36
9,105.47
6,323.62

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Cash From Operating Activity
2,152.45
1,813.30
919.78
1,137.24
PBT
2,399.36
1,671.24
1,974.60
1,691.61
Adjustment
212.20
298.43
30.81
-5.66
Changes in Working Capital
20.42
166.73
-586.12
-94.63
Cash after chg. in Working capital
2,631.98
2,136.40
1,419.29
1,591.32
Interest Paid
0.00
0.00
0.00
0.00
Tax Paid
-479.53
-323.10
-499.51
-454.07
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,081.69
-1,054.13
-1,369.14
-1,222.21
Net Fixed Assets
-259.53
-591.49
-2,286.21
Net Investments
-1,327.90
-576.36
-128.98
Others
-494.26
113.72
1,046.05
Cash from Financing Activity
5.27
-739.73
604.62
-7.81
Net Cash Inflow / Outflow
76.02
19.44
155.26
-92.78
Opening Cash & Equivalents
304.82
283.06
127.33
219.73
Closing Cash & Equivalent
382.01
304.82
283.06
127.33

Financial Ratios

Standalone /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Mar 21
Book Value (Rs.)
233.15
185.61
153.65
117.88
ROA
18.01%
13.94%
18.83%
22.79%
ROE
23.15%
19.27%
26.72%
31.51%
ROCE
28.38%
23.49%
33.96%
39.97%
Fixed Asset Turnover
1.93
1.92
2.52
3.00
Receivable days
24.18
19.33
16.25
25.31
Inventory Days
51.80
65.31
66.57
61.16
Payable days
120.04
130.57
131.38
144.73
Cash Conversion Cycle
-44.05
-45.92
-48.56
-58.26
Total Debt/Equity
0.02
0.02
0.14
0.05
Interest Cover
69.46
37.52
34.02
80.96

News Update:


  • Mankind Pharma completes transaction to acquire 100% stake in Bharat Serums and Vaccines
    24th Oct 2024, 09:39 AM

    BSV’s established domestic product portfolio offers huge scalability potential through strong registration velocity through niche filings across international markets

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.